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Edited by Francesc PosasAbstract We investigated the mechanism of 8-Br-cAMP-medi-
ated phospholipase D (PLD) activation using a primary cell cul-
ture system of human endometrial stromal cells (ES cells). PLD
activity was increased by the treatment of ES cells with 8-Br-
cAMP, maximally at 5 min. To determine whether the eﬀects
of 8-Br-cAMP on PLD occurred as a consequence of PKC acti-
vation, ES cells were preincubated for 15 min with RO320432
(1 lM) and GF109203X (1 lM), the PKC inhibitors, or they
were pretreated for 24 h with phorbol myristate acetate
(100 nM) to downregulate PKC. However, these treatments
had no eﬀects on PLD activation induced by 8-Br-cAMP. Fur-
thermore, 8-Br-cAMP had no eﬀects on the subcellular distribu-
tion of PKC a and PKC bI, conﬁrming no involvement of PKC.
8-Br-cAMP activated ERK1/2, maximally at 5 min, and
PD98059 (MEK inhibitor: 50 lM) and transfection of ES cells
with dominant negative (DN)-MEK completely inhibited 8-
Br-cAMP-induced PLD activation, suggesting that ERK1/2
mediates the PLD activation. To investigate the involvement of
protein kinase A (PKA), Src, and Ras in 8-Br-cAMP-induced
PLD activation, we used PKA inhibitor, H89 and Rp-cAMPs,
and transfections of DN-Src and DN-Ras. H-89 and Rp-cAMPs
completely blocked 8-Br-cAMP-mediated PLD and ERK acti-
vation, implying the involvement of PKA in this PLD activation.
In addition, transfection of ES cells with DN-Src, or DN-Ras
partially inhibited 8-Br-cAMP-induced ERK1/2 and conse-
quently PLD activation, whereas cotransfection of DN-Src and
DN-Ras completely inhibited ERK1/2 and PLD activation, sug-
gesting that Src and Ras independently regulate ERK/PLD acti-
vation. Taken together, these results demonstrate a novel
pathway in ES cells that 8-Br-cAMP activate PLD through
PKA and ERK1/2 and this ERK/PLD activation by 8-Br-cAMP
is mediated by Src and Ras, separately.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Decidualization, a process of endometrial diﬀerentiation, is
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doi:10.1016/j.febslet.2005.09.034nancy [1]. During the process of decidualization, dramatic
morphological and functional changes occur. Evidence has
emerged to suggest that initiation of the decidual process re-
quires elevated intracellular cAMP and sustained activation
of the protein kinase A (PKA) [2]. Upon withdrawal of the
cAMP stimulus, in vitro decidualized human endometrial stro-
mal cells (ES cells) reacquire an undiﬀerentiated phenotype
and cease to express diﬀerentiation markers such as PRL
and IGFBP-1 [1]. Therefore, many studies have addressed
the underlying mechanisms of the cAMP signaling [3,4]: how-
ever, our knowledge regarding the overall picture of cAMP sig-
naling pathway involved in decidualization is preliminary at
best.
In recent years, several lines of evidence demonstrated the
importance of phospholipase D (PLD) as intracellular regula-
tor. PLD catalyzes the hydrolysis of phospholipids at their ter-
minal phosphodiester bond, thus producing phosphatidic acid
(PA) and releasing the free polar head group [5]. PA, acting as
a second messenger, can further be converted to other messen-
ger molecules such as 1, 2-diacylglycerol and lysophosphatidic
acid [6]. Two types of PLD have been cloned, PLD1 and
PLD2: PLD1 is present throughout the cell, but particularly
in perinuclear, Golgi, and heavy membrane fractions, whereas
PLD2 is located almost exclusively on plasma membrane in the
light membrane ‘‘lipid raft’’ fractions. PLD1 is activated by
protein kinase C (PKC) and small GTP-binding proteins, such
as ADP-ribosylation factor (ARF) and Rho. In contrast,
PLD2 is constitutively active in vitro, and its activity is ele-
vated by fatty acid, but not by GTPases or PKC a [7,8]. Sev-
eral cytokines, growth factors, hormones, or neurotransmitters
stimulate PLD activity in various tissues or cell systems. Acti-
vation of 8-Br-cAMP-induced pathway has recently been
implicated in the stimulation of PLD in many cell types. Gins-
berg et al. [9] demonstrated that cAMP agonists activated PLD
via PKA in FRTL-5 thyroid cells, and Ruan et al. [10] reported
that PLD in Rat-1 ﬁbroblasts was activated by treatment with
forskolin, which directly activates adenylyl cyclase and in-
creases the intracellular concentration of cAMP, thereby
increasing PKA activity. However, the mechanism by which
PLD is regulated by cAMP is not known.
The purpose of the present study was to determine whether
cAMP activated PLD in human ES cells. We demonstrated that
cAMP-induced-PLD activation was dependent on PKA and
ERK1/2, but not on PKC. This novel mechanism of cAMP-
stimulated ERK/PLD activation appears to be regulatedation of European Biochemical Societies.
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this is the ﬁrst report that cAMP signaling is related to PLD
activation in human ES cells.2. Materials and methods
2.1. Materials
Materials for tissue culture, such as fetal bovine serum (FBS),
penicillin, streptomycin, and Dulbeccos modiﬁed Eagles medium
(DMEM, low glucose) were obtained from Gibco-BRL (Grand Is-
land, NY, USA), and 8-Br-cAMP, phorbol 12-myristate 13-acetate
(PMA), and PD98059 from Sigma (St. Louis, MI, USA). The
PKC inhibitors, RO 320432 and GF109203X, and PKA inhibitors,
H-89 and Rp-cAMPs were obtained from Calbiochem (Nottingham,
UK), and [3H]-palmitic acid was from Du Pont-New England Nu-
clear (Boston, MA, USA). pCMV-MEK2A was obtained from G.
Johnson of the National Jewish Medical Research Center (Denver,
CO). pcDNA3.1-H-Ras N17 [11] was obtained from David Stokoe
of ONYX Pharmaceuticals (Richmond, CA, USA). Dominant neg-
ative (DN)-Src (K296R/Y528F) was purchased from Upstate bio-
technology (Lake Placid, NY, USA). Antibodies used were as
follows: ERK1/2 polyclonal antibody, p-ERK1/2 monoclonal anti-
body, MEK polyclonal antibody, PKC isozymes, Src monoclonal
antibody (Cell signaling, USA), and Ras monoclonal antibody
(Oncogenes research products, USA). A polyclonal antibody that
recognizes both PLD1 and PLD2 was provided by Dr. D.S. Min
(Pusan National University, Korea), L-a-phosphatidylbutanol
(PBt) was from Avanti Polar Lipid Inc. (Alabaster, AL, USA),
and the silica gel 60A plates for TLC were purchased from What-
man (Clifton, NJ, USA). All other chemicals were of analytical
grade.
2.2. Isolation and culture of human ES cells
Human endometria were obtained at hysterectomy of normally
cycling pre-menopausal women, aged 35–44 years, who underwent
surgery for non-endometrial abnormalities. A portion of each endome-
trial specimen obtained was examined histologically. ES cells were iso-
lated as described previously [12]. Brieﬂy, tissue samples were collected
in DMEM containing 100 IU/ml penicillin, 100 lg/ml streptomycin,
2 mM L-glutamine, and 10% FBS. After cleaning and trimming to re-
move blood clots and mucus, the specimens were minced to fragments
less than 1 mm in size under a laminar ﬂow hood and then digested for
60 min at 37 C with 0.25% collagenase I (Sigma chemical Co., St.
Louis, MO, USA) and deoxynuclease (Sigma Chemical Co., St. Louis,
MO, USA): After enzymatic digestion, most of stromal cells were pres-
ent as single cells or small aggregates. The cell suspension was ﬁltered
through a 40 lm sieve (BD Falcon, MA, USA) twice. The purity of
stromal cells obtained by this method was usually >90%, as determined
by immunocytochemical staining against vimentin (stromal marker).
The puriﬁed stromal cells were washed, and the numbers of viable cells
were counted by dye exclusion, using trypan blue and the viability of
isolated cells was at least 90% in each experiment. Cells were cultured
at 37 C in a humidiﬁed atmosphere of 5% CO2 in air with 4 mL of
DMEM supplemented with 10% FBS, 100 IU/ml penicillin, and
100 lg/ml streptomycin.
2.3. Determination of PLD activity
PLD activity was determined as previously described by measuring
[3H]-PBt produced via PLD-catalyzed transphosphatidylation in
[3H]-palmitic acid labeled cells [13]. Brieﬂy, ES cells cultured on 6-well
plates were metabolically labeled with 1 lCi/ml of [3H]-palmitate for
18 h. The cells were then pretreated with 0.3% (vol/vol) 1-butanol for
15 min before stimulation with 8-Br-cAMP. After the stimulation,
the cells were quickly washed with ice-cold phosphate-buﬀered saline
(PBS) and suspended in ice-cold methanol. Lipids were extracted
according to the method of Bligh and Dyer [14], and [3H]-PBt was
separated from other phospholipids by thin layer chromatography
on Silica G-60 plates, using a solvent system of ethyl acetate/iso-oc-
tane/acetic acid/water (130:20:30:100, v/v). The regions corresponding
to the authentic PBt bands were identiﬁed with 0.002% (wt/vol) primu-
lin in 80% (vol/vol) acetone, scraped and counted by a scintillation
counter.2.4. Preparation of cytosol and membrane fraction
Serum-starved cells were incubated with 8-Br-cAMP (0.5 mM) for 5
or 30 min, scraped in ice-cold PBS and harvested by microcentrifuga-
tion. The cells were then resuspended in a buﬀer solution [50 mM
NaCl, 1 mM MgCl2, 2 mM EDTA, 1 mM DTT, 1 mM PMSF,
10 lg/ml aprotinin, 10 lg/ml leupeptin, 50 mM HEPES, pH 7.5], and
disrupted by sonication, and centrifuged for 100000 · g for 1 h. The
supernatant was used as the cytosolic fraction, and the pellet (mem-
brane fraction) was resuspended in lysis buﬀer containing 1% (v/v)
Triton X-100.
2.5. Western blot analysis
ES cells were scraped in ice-cold PBS and harvested by microcentrif-
ugation. The cells were then resuspended in a buﬀer solution [20 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
2.5 mM sodium pyrophosphate, 1% Triton X-100, 1 mM PMSF, and
1 mM Na3VO4] and disrupted by sonication. Proteins were resolved
by 10% sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) and transferred onto nitrocellulose membranes. The
membranes were blocked for 1 h with TTBS (Tris-buﬀered saline con-
taining 0.01% Tween 20) containing 5% (w/v) non-fat dried skimmed
milk and incubated for additional 1 h with primary antibodies (1 lg/
ml). Unbound primary antibodies were removed by three washes
(10 min each) with TTBS. The blots were then incubated with horse-
radish peroxidase (HRP)-conjugated secondary antibody (1:2000,
New England Biolabs Inc., Beverly, MA, USA), and speciﬁc bands
were detected by enhanced chemiluminescence (ECL; Amersham Phar-
macia Biotech, England).
2.6. Transfection
ES cells expanded for 4–6 days were transfected by using Nucleofec-
tor Kit (Amaxa, Germany) as described by the manufacturers proto-
col. Transfection controls were carried out with the same amount of
vector. Twenty-four hours after transfection, the cells were serum-
starved for 18 h and then treated with 0.5 mM 8-Br-cAMP. Western
blot analysis for expression of plasmid DNA as an internal control
was used to determine the transfection eﬃciency.
2.7. Statistical analysis
All experiments were performed at least three to ﬁve times, and data
were analyzed using one-way ANOVA and considered to be signiﬁ-
cantly diﬀerent at P < 0.05.3. Results
3.1. Eﬀects of 8-Br-cAMP on PLD activity in ES cells
cAMP eﬀectively induces decidualization in vitro [1], and
maximal eﬀect of 8-Br-cAMP was observed at 0.5 mM and
an apparent decline at higher levels [2]. Therefore, to determine
the eﬀect of 8-Br-cAMP on PLD activity, ES cells labeled with
[3H]-palmitic acid were treated with 0.5 mM cAMP, and [3H]-
PBt produced by PLD-catalyzed transphosphatidylation was
quantitated by TLC analysis. As shown in Fig. 1A, treatment
of ES cells with 0.5 mM 8-Br-cAMP maximally increased PLD
activity up to 220% at 5 min. We next examined the eﬀects of
cell passage on PLD activity. As shown in Fig. 1B, 8-Br-cAMP
induced PLD activity slightly decreased with the passage of ES
cells: Therefore, we selected ES cells of passage 1. Subse-
quently, in order to examine whether the increase of PLD
activity was resulted from the increased de novo PLD synthe-
sis, we quantitated the PLD protein expression by Western
blot analysis after treatment of ES cells with 8-Br-cAMP. As
seen in Fig. 1C, PLD1 and PLD2 protein expression levels
did not change within 1 h, indicating that upregulation of
PLD activity within 1 h was not due to increased PLD protein
level, but rather most likely due to the presence of PLD activa-
tion pathway.
Fig. 1. Time-dependent activation of PLD by 8-Br-cAMP, eﬀect of
passage on 8-Br-cAMP-induced PLD activation, and changes of PLD
expression level by 8-Br-cAMP in ES cells. (A) ES cells (0.5 · 106 cells/
well) were labeled with 1 lCi/ml [3H]-palmitic acid and then stimulated
with 0.5 mM 8-Br-cAMP for diﬀerent times. PLD activities were then
determined by estimating the amount of [3H]-PBt in the presence of 1-
butanol. Results are means ± S.D. from four independent experiments.
(B) ES cells from diﬀerent passage were labeled with 1 lCi/ml [3H]-
palmitic acid and then PLD activity was measured by estimating the
formation of PBt (P-1, passage 1; P-2, passage 2; P-3, passage 3). (C)
ES cells treated with 8-Br-cAMP for the indicated times were lysed.
Each fraction containing 30 lg of protein was analyzed by 10% SDS–
PAGE and subsequent Western blotting using anti-PLD polyclonal
antibody. Bands were shown by ECL. The intensity of bands was
quantiﬁed using QuantityOne software (Bio-Rad, USA). All determi-
nations were carried out on three diﬀerent cell lysates.
Fig. 2. Eﬀects of PKC downregulation on 8-Br-cAMP-induced PLD
activation and eﬀects of 8-Br-cAMP on PKC translocation in ES cells.
(A) ES cells (0.5 · 106 cells/well) were labeled with 1 lCi/ml [3H]-
palmitic acid and then pretreated with RO320432 or GF109203X
(1 lM, each) for 15 min before measurement of relative PLD activity.
PLD activities were determined by estimating the formation of [3H]-
PBt in the presence of 1-butanol. Results are mean ± SD from three
independent experiments. (B) ES cells (0.5 · 106 cells/well) were treated
in the absence or presence of 200 nM PMA for 24 h. The cells were
labeled with 1 lCi/ml [3H]-palmitic acid and then pretreated with 0.3%
(v/v) 1-butanol for 15 min before stimulation with 0.5 mM 8-Br-cAMP
or 200 nM PMA. PLD activities were determined by estimating the
formation of [3H]-PBt in the presence of 1-butanol. Results are
means ± S.D. from four independent experiments. (C) Serum-starved
ES cells (3 · 106 cells/dish) were stimulated with 0.5 mM 8-Br-cAMP
for 5 or 30 min. As a positive control for PKC translocation to plasma
membrane, cells treated with 200 nM PMA for 30 min were also
prepared. The cells were then lysed, and subjected to subcellular
fractionation into cytosol and membrane fractions by centrifugation at
100000 · g, and each fraction containing 30 lg of protein was
analyzed by 10% SDS–PAGE and subsequently Western blotting
using anti-PKC a and PKC bI polyclonal antibody.
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activation
PKC is the major regulator of PLD activity in many cell
types [15]. Therefore, to determine whether PLD was activated
via PKC activation, three experimental approaches were
taken. The ﬁrst approach was to inhibit PKC activity withPKC inhibitors such as RO 320432 and GF109203X. As
shown in Fig. 2A, when ES cells were pretreated with RO
320432 (1 lM) or GF109203X (1 lM) for 15 min, PMA-in-
duced-PLD activity decreased by 77% and 68%, respectively.
However, these pretreatments did not decrease the level of
Fig. 3. Eﬀects of 8-Br-cAMP on ERK phosphorylation in ES cells. (A)
To measure ERK phosphorylation, cells (3 · 106 cells/dish) were
pretreated with 0.1 mM vanadate, followed by stimulation with 8-Br-
cAMP for indicated times. Lysates were immunoblotted with anti-
ERK1/2 and -p-ERK1/2. The intensity of bands was quantiﬁed using
QuantityOne software (Bio-Rad, USA). Data represent the results of
three separate experiments. (B) ES cells (0.5 · 106 cells/well) were
labeled with 1 lCi/ml [3H]-palmitic acid and then pretreated with
PD98059 (50 lM) for 30 min before stimulation with 0.5 mM 8-Br-
cAMP. PLD activities were determined by estimating the formation of
[3H]-PBt in the presence of 1-butanol. Results are means ± S.D. from
three independent experiments.
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Br-cAMP-mediated PLD activation in ES cells was studied
after desensitization of PKC by long-term stimulation with
PMA. As shown in Fig. 2B, PKC downregulation decreased
the extent of PMA-mediated PLD activation by approximately
90%, whereas it decreased 8-Br-cAMP-mediated PLD activa-
tion only by approximately 10%. Finally, to further conﬁrm
that PKC activation was not involved in 8-Br-cAMP-induced
PLD activation, we investigated the eﬀects of 8-Br-cAMP on
PKC translocation in ES cells since PKC translocation has
been regarded as a process in the activation of PKC [16]. As
shown in Fig. 2C, 8-Br-cAMP treatment did not change the
amounts of PKC a and PKC bI in membrane fraction after
5 and 30 min; PMA was used as the positive control for
PKC translocation. Furthermore, the subcellular distributions
of other PKC isoforms (e, d) were not changed by 8-Br-cAMP
treatment (data not shown). Taken together, these results sug-
gest that PKC is not involved in 8-Br-cAMP-induced PLD
activation in ES cells, leading us to suggest the presence of an-
other regulatory mechanism.3.3. ERK1/2 is involved in 8-Br-cAMP-mediated PLD activation
in ES cells
One of the targets of cAMP is the mitogen-activated pro-
tein kinase. When cAMP activates ERK, it can stimulate cell
diﬀerentiation as well as proliferation [17]. To gain an insight
into PLD activation pathway in ES cells, we analyzed the
phosphorylation of ERK1/2 within 60 min after treatment
with 0.5 mM 8-Br-cAMP. A time-course analysis showed that
8-Br-cAMP induced rapid activation of ERK1/2, maximally
in 5 min (Fig. 3A). The phosphorylation of SAPK/JNK and
P38 did not change within 1 h (data not shown). Next, to
determine whether ERK phosphorylation has any inﬂuence
on 8-Br-cAMP-induced PLD activation, PD98059 (50 lM),
MEK inhibitor, was used to block the activity of ERK1/2.
When the cells were pretreated with PD98059 for 30 min,
8-Br-cAMP-induced PLD activation was completely abol-
ished by the inhibitor (Fig. 3B). Since pharmacological agents
may exert non-speciﬁc eﬀects, a dominant negative form of
MEK (DN-MEK) was used in the next experiment. When
ES cells were transfected with DN-MEK by electrophoration,
the eﬃciency of transfection, determined by Western blot
analysis, indicated successful transfection of DN-MEK
(Fig. 4A). Consistent with the result of PD98059 described
above, the expression of DN-MEK attenuated 8-Br-cAMP-
induced ERK phosphorylation (Fig. 4A) and PLD activation
(Fig. 4B). Therefore, these results indicate that ERK1/2
participates in 8-Br-cAMP-stimulated PLD activation in ES
cells.
3.4. PKA is upstream components of 8-Br-cAMP-induced
ERK/PLD activation
In ES cells, cAMP activates PKA, which may phosphorylate
target molecules in the cytoplasm or diﬀuses into nucleus and
modulates activity of transcription factors by phosphorylation
[18]. Hence, we tested the possible involvement of PKA in 8-
Br-cAMP-induced ERK1/2 and PLD activation. When the
cells were pretreated with PKA inhibitors such as H-89
(10 lM) and Rp-cAMPs (100 lM) for 30 min, 8-Br-cAMP-in-
duced ERK phosphorylation and PLD activation were com-
pletely blocked (Fig. 5A and B). Taken together, these
results suggest that PKA plays a major role in ERK/PLD acti-
vation pathway after treatment with 8-Br-cAMP.
3.5. Ras and Src independently mediated 8-Br-cAMP-induced
ERK/PLD activation
Since Src is activated by phosphorylation on Ser17 which is
also the site targeted by PKA [19] and Ras participates in
cAMP-induced ERK activation [20], we next examined
whether Src and Ras are involved in 8-Br-cAMP-induced
ERK1/2 and PLD activation. To rule out the possibility of
non-speciﬁc inhibition of pharmacological inhibitors, we em-
ployed dominant negative forms of Src (DN-Src) and Ras
(DN-Ras). Thus, the plasmid encoding DN-Src DNA and
DN-Ras DNA were introduced into the cells by electrophora-
tion, and the cells were then stimulated by 8-Br-cAMP for
5 min. As shown in Fig. 6A, the levels of PLD1 and PLD2
expression did not change in DN-Src and/or DN-Ras transfec-
tants. However, the phosphorylation of ERK1/2 decreased by
82% in the DN-Src and 63% in the DN-Ras expressing cells,
respectively. On the other hand, cotransfection of ES cells with
DN-Src and DN-Ras completely inhibited the 8-Br-cAMP-
induced ERK1/2 activation, indicating that Src and Ras
Fig. 4. Eﬀects of the dominant negative form of MEK (DN-MEK) on
8-Br-cAMP-induced ERK phosphorylation and PLD activation in ES
cells. (A) ES cells were transfected with DN-MEK or vector, followed
by stimulation with 8-Br-cAMP for 5 min. Lysates were immunoblot-
ted with anti-ERK1/2 and -p-ERK1/2 antibodies. The intensity of
bands was quantiﬁed using QuantityOne software (Bio-Rad, USA).
Data represent the results of three separate experiments. (B) Trans-
fected ES cells (0.5 · 106 cells/well) were labeled with 1 lCi/ml [3H]-
palmitic acid and stimulated with 0.5 mM 8-Br-cAMP for 5 min. PLD
activities were determined by estimating the formation of [3H]-PBt in
the presence of 1-butanol. Results are means ± S.D. from three
independent experiments.
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with these results, the 8-Br-cAMP-induced PLD activation in
the DN-Src and DN-Ras transfectants were partially de-
creased by 57% and 26%, respectively, compared to control
empty vector transfectants, whereas in cotransfectants with
DN-Src and DN-Ras it was completely abolished (Fig. 6B),
implying that Src and Ras are partial regulators of 8-Br-
cAMP-induced PLD stimulation. Taken together, these results
suggest that Src and Ras independently mediate 8-Br-cAMP-
induced ERK1/2/PLD activation.4. Discussion
In human ES cells, cAMP is a strong inducer of decidualiza-
tion, a process of dramatic change in their biochemical
properties as well as morphological appearance. However,
cAMP-induced intracellular signaling pathways leading to
decidualization are still far from clear. In the present study,we investigated for the ﬁrst time the mechanism by which
cAMP activates PLD in human ES cells, and demonstrated
that 8-Br-cAMP activated PLD through PKA-dependent
pathway. We also observed that ERK1/2 mediates cAMP-in-
duced PLD stimulation via PKA. Moreover, we found that
Src and Ras are the downstream components of PKA, which
mediate cAMP-induced ERK1/2/PLD activation.
In the present study, 8-Br-cAMP (0.5 mM) activated PLD
maximally at 5 min; however, it did not change the expression
level of PLD1 and PLD2. Therefore, cAMP-induced PLD acti-
vation may be due to cAMP-induced signaling pathway. First,
we tested whether PKC was involved in 8-Br-cAMP-induced
PLD activation, because PKC is a well-known activator
of PLD. However, our results showed that 8-Br-cAMP-in-
duced PLD activity in ES cells is independent of PKC: PKC
inhibitors (RO 320432, GF109203X) did not block the increase
of PLD activity elicited by 8-Br-cAMP, and long-term treat-
ment with PMA (24 h), which depletes PKC, also failed to al-
ter the PLD activation. As we expected, there was also no
translocation of PKC isoforms to membranes following 8-
Br-cAMP exposure. On the other hand, H-89 and Rp-cAMPs,
PKA inhibitor, completely blocked the 8-Br-cAMP-induced
PLD stimulation, suggesting that 8-Br-cAMP elicited its eﬀects
via PKA activation. These results are in good agreement with
previous reports that, in some cell systems, cAMP agonists in-
duce PLD activation via PKA, not via PKC: In FRTL-5 thy-
roid cells, dibutyryl cAMP and foskolin, which stimulates
adenyl cyclase and accumulates cAMP, induced PLD activa-
tion through PKA activation [9], and elevation of cAMP in
tracheal smooth muscle cells takes as little as 5 min to signiﬁ-
cantly increase the level of PLD and PKA inhibitors signiﬁ-
cantly decrease foskolin-mediated PLD activation [21].
In the present study, we also found that 8-Br-cAMP stimu-
lated the activation of ERK1/2, but not SAPK/JNK and P38,
and the failure of 8-Br-cAMP to activate P38 and SAPK/JNK
indicates that 8-Br-cAMP speciﬁcally activates ERK1/2 in ES
cells. Based on our following observation, we propose that
cAMP-induced ERK1/2 activation regulates PLD in ES cells.
PD98059 (50 lM), the inhibitor of MEK, attenuated the in-
crease of ERK1/2 and PLD activation induced by 8-Br-cAMP
in ES cells. ERK cascade has been implicated in chemoattrac-
tant fMet-Leu-Phe [22], norepinephrine-induced PLD activa-
tion [23] as well as oxidative stress-induced PLD activation
[24]. Recently, Robin et al. [25] reported that 1-butanol,
PLD inhibitor, decreased endothelin-1 (ET-1)-induced ERK
activation in rat uterine leiomyoma cells, suggesting that ET-
1 induced PLD-dependent ERK activation. However, in our
study, the pretreatment of ES cells with 1-butanol did not
change cAMP-induced ERK activation, conﬁrming that
ERK is an upstream regulator of PLD activation (data not
shown). The mechanism of PLD regulation by the ERK cas-
cade remains unknown, and may possibly occur through both
direct and indirect regulatory processes. A potential direct pro-
cess has been suggested by the observation that several proline-
rich sequences predictive of serine phosphorylation by ERK
are present in the gene of PLD2 isoform [26], and Muthalif
et al. [22] demonstrated that PLD1 is directly phosphorylated
by puriﬁed ERK, leading to increased activity. In indirect reg-
ulation, on the other hand, it may occur through recruitment
and membrane association of PLD regulatory proteins such
as small GTPase RhoA and ARF [7]. ERK may also be acti-
vated in response to PA production by PLD, and PA has been
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contribution of such processes and other mechanisms in the
regulation of PLD activity by the ERK cascade demands
further studies.
It has been reported that numerous mechanisms exist to al-
low cAMP to activate ERK signaling. In stimulation of ERK
by cAMP, the pathway by which cAMP activates ERK de-
pends on cell type [28]. In the case of ES cells, cAMP activates
ERK1/2 via PKA, since pretreatment of the cells with H-89
and Rp-cAMPs inhibited ERK phosphorylation. Concur-
rently, these pretreatments blocked cAMP-induced PLD acti-
vation, thus indicating that PKA on the upstream of ERK
regulated PLD. In addition, based on the following observa-
tions we suggest that Src and Ras are upstream regulators of
ERK/PLD and they are independently involved in ERK/
PLD activation: (1) Expression of DN-Src or DN-Ras par-
tially inhibited cAMP-induced ERK1/2 phosphorylation (by
82% and 63%, respectively), and PLD activation (by 57%
and 26%, respectively). (2) Cotransfection of DN-Src andFig. 5. Eﬀects of H-89 and Rp-cAMPs on 8-Br-cAMP-induced ERK phosph
with H-89 and Rp-cAMPs for 30 min, followed by stimulation with 8-Br-cA
ERK1/2 antibodies. The intensity of bands was quantiﬁed using QuantityOne
experiments. (B) ES cells (0.5 · 106 cells/well) were labeled with 1 lCi/ml [3H]-
before stimulation with 0.5 mM 8-Br-cAMP for 5 min. PLD activities were d
butanol. Results are means ± S.D. from three independent experiments.DN-Ras completely inhibited the cAMP-induced ERK1/2
and PLD activation. Recent studies show that ERK activation
by PKA requires members of Src families [29,30]. In brown
adipocytes and primary sertoil cell, PKA-mediated ERK phos-
phorylation was inhibited by the Src inhibitor, PP2, in support
of our results. Moreover, Ras is known to participate in cAMP
signaling under certain circumstances: There are recent reports
that cAMP and PKA require Ras to activate ERK in hippo-
campus neuron and cortical neuron [31,32]. In melanocytes,
ERK activation by cAMP requires both Ras and B-Raf [33].
In addition, Ras and Src have been reported to be regulators
of PLD activity. v-Src activated a PLD activity in BALB/c
3T3 cells, which can be distinguished from the PLD activity in-
duced by phorbol esters that activate PKC [34]. Jiang et al. [35]
reported that Ras plays a role in PLD activation by v-Src, but
PLD is not a direct target of Ras. These reports support our
results that Ras and Src are involved in PLD activation. Our
results are the ﬁrst indication that cAMP/PKA activate
ERK/PLD via Ras and Src independently in human ES cells.orylation and PLD activation in ES cells. (A) ES cells were pretreated
MP for 5 min. Lysates were immunoblotted with anti-ERK1/2 and -p-
software (Bio-Rad, USA). Data represent the results of three separate
palmitic acid and then pretreated with H-89 and Rp-cAMPs for 30 min
etermined by estimating the formation of [3H]-PBt in the presence of 1-
Fig. 6. Eﬀects of DN-Src and DN-Ras on 8-Br-cAMP-induced
ERK phosphorylation and PLD activation in ES cells. (A) ES cells
were transfected with DN-Src, DN-Ras, or vector, followed by
stimulation with 8-Br-cAMP for 5 min. The intensity of bands was
quantiﬁed using QuantityOne software (Bio-Rad, USA). Data repre-
sent the results of three separate experiments. (B) Transfected ES cells
(0.5 · 106 cells/well) were labeled with 1 lCi/ml [3H]-palmitic acid and
stimulated with 0.5 mM 8-Br-cAMP for 5 min. PLD activities were
determined by estimating the formation of [3H]-PBt in the presence
of 1-butanol. Results are means ± S.D. from three independent
experiments.
Fig. 7. The proposed model for the signaling pathway of PLD
activation induced by 8-Br-cAMP in ES cells. Our data suggest that 8-
Br-cAMP activates ERK1/2 and PLD through PKA, not through
PKC. 8-Br-cAMP activates PKA, and subsequently PKA delivers the
signal to Src and Ras, respectively. Src and Ras regulate MEK/ERK1/
2 activation independently.
M.-S. Yoon et al. / FEBS Letters 579 (2005) 5635–5642 5641In conclusion, the present study provides evidence that 8-
Br-cAMP-induced PLD activation is mediated through
PKA-ERK1/2 and is independently regulated by Ras and
Src (Fig. 7). Further studies such as elucidation of molec-
ular mechanism by which ERK1/2 regulates PLD in ES
cells are expected to provide greater insight into the under-
standing of cAMP-induced PLD activation and decidualiza-
tion.Acknowledgement: This work was supported by a grant from the Kor-
ea Research Foundation (015-E00070, 2004) and partially supported
by the KOSEF and MOST through the Research Center for Biomedic-
inal Resources (Bio-Med RRC), PaiChai University.References
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